纳武单抗导致Stevens-Johnson综合征1例

图 1 患者治疗前皮损

下载: 全尺寸图片幻灯片

图 2 患者皮损病理

A：左前臂皮损（H&E染色×40）；B：左前臂皮损（H&E染色×200）

下载: 全尺寸图片幻灯片

图 3 患者治疗后皮损

下载: 全尺寸图片幻灯片

[1]	Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor[J]. Eur J Cancer, 2016, 60:12-25. doi: 10.1016/j.ejca.2016.02.010
[2]	Sibaud V. Dermatologic reactions to immune checkpoint inhibitors:skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3):345-361. doi: 10.1007/s40257-017-0336-3
[3]	Zhang AJ, Nygaard RM, Endorf FW, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis:retrospective review of 10-year experience[J]. Int J Dermatol, 2019, 58(9):1069-1077. doi: 10.1111/ijd.14409
[4]	Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome during nivolumab treatment of NSCLC[J]. Ann Oncol, 2018, 29(1):283-284. doi: 10.1093/annonc/mdx640
[5]	Buchbinder E, Desai A. CTLA-4 and PD-1 pathways:similarities, differences, and implications of their inhibition[J]. Am J Clin Oncol, 2016, 39(1):89-106. http://cn.bing.com/academic/profile?id=686e2f197b85d3ff2f9de10c7a5edc76&encoded=0&v=paper_preview&mkt=zh-cn
[6]	Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients[J]. Eur J Cancer, 2017, 81:237-239. doi: 10.1016/j.ejca.2017.03.026
[7]	Hwang A, Iskandar A, Dasanu CA. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy[J]. J Oncol Pharm Pract, 2019, 25(6):1520-1522. doi: 10.1177/1078155218791314